Nurix Therapeutics Income Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Revenue	71.78	83.98	54.55	76.99	38.63	29.75
Revenue Growth (YoY)	27.23%	53.95%	-29.14%	99.31%	29.84%	66.95%
Gross Profit	71.78	83.98	54.55	76.99	38.63	29.75
Selling, General & Admin	55.7	52.74	45.94	42.9	38	31.2
Research & Development	331.38	316.9	221.63	189.15	184.5	116.43
Total Operating Expenses	387.08	369.65	267.58	232.05	222.49	147.64
Operating Income	-315.3	-285.67	-213.03	-155.06	-183.87	-117.89
Total Non-Operating Income (Expense)	20.78	21.97	19.73	11.12	3.51	0.82
Pretax Income	-207.35	-263.7	-193.3	-143.95	-180.36	-117.06
Provision for Income Taxes	0.76	0.76	0.27	-	-	0.13
Net Income	-208.11	-264.46	-193.57	-143.95	-180.36	-117.19
Net Income to Common	-295.28	-264.46	-193.57	-143.95	-180.36	-117.19
Shares Outstanding (Basic)	93	87	67	54	49	43
Shares Outstanding (Diluted)	93	87	67	54	49	43
Shares Change (YoY)	25.60%	29.12%	23.52%	11.79%	13.32%	173.68%
EPS (Basic)	-3.16	-3.05	-2.88	-2.65	-3.71	-2.73
EPS (Diluted)	-3.16	-3.05	-2.88	-2.65	-3.71	-2.73
Free Cash Flow	-125.3	-263.47	-182.14	-89.48	-172.05	-90.03
Free Cash Flow Per Share	-1.34	-3.04	-2.71	-1.65	-3.54	-2.10
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-439.26%	-340.16%	-390.52%	-201.41%	-476.01%	-396.25%
Profit Margin	-289.93%	-314.90%	-354.85%	-186.98%	-466.93%	-393.93%
FCF Margin	-174.56%	-313.73%	-333.91%	-116.23%	-445.42%	-302.61%
EBITDA	-305.38	-266.81	-196.6	-141.41	-173.06	-111.8
EBITDA Margin	-425.44%	-317.71%	-360.41%	-183.68%	-448.03%	-375.81%
EBIT	-315.3	-285.67	-213.03	-155.06	-183.87	-117.89
EBIT Margin	-439.26%	-340.16%	-390.52%	-201.41%	-476.01%	-396.25%
Effective Tax Rate	-0.37%	-0.29%	-0.14%	0.00%	0.00%	-0.11%

SEC Filings: 10-K · 10-Q